➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Mallinckrodt
Boehringer Ingelheim
Dow
McKinsey

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

Litigation Details for In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation (D. Mass. 2014)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation (D. Mass. 2014)

Date Filed Document No. Description Snippet Link To Document
2018-01-12 931 U.S. Patent No. 7,541,347 (“’347 Patent”), U.S. Patent No. 7,544,373 (“’373 Patent”), U.S. Patent No. …including U.S. Patent No. 5,908,838 (“’838 patent”) and U.S. Patent No. 7,790,705 (“’705 Patent”). Additionally…7,919,483 (“’483 Patent”), U.S. Patent No. 8,268,804 (“’804 Patent”), and U.S. Patent No. 8,252,776 (“…expert, a patent law professor, to opine on a patent litigant’s chances of success in a patent suit), aff…infringement of Medicis’s patents, as well as the timeline for Impax-Medicis patent litigation. Defendants External link to document
2018-01-25 948 issued an additional patent to Medicis—U.S. Patent No. 7,790,705 (the “’705 patent”), covering “the method… 30. Medicis holds U.S. Patent No. 5,908,838 (the “’838 patent”), a “[m]ethod for the [t]reatment…reexamination of the ’838 patent, and in June 2010, the United States Patent …the ’838 patent was invalid for obviousness. D. 850 at 17. Subject matter cannot be patented if “the …analyses of multiple Solodyn patents; it is not specific to the ’838 patent. See Kibbe 19 Kibbe’s External link to document
2018-01-25 963 if additional information had been submitted.8' 9 Id. at *18-21. Accordingly, Plaintiffs' cases…FOR THOMAS'S OPINION ON TECHNICAL PATENT ISSUES Patent law experts are not qualified to opine…expert to opine on the validity of [the] patent was patently inappropriate and frivolous" and then…"patent law expert [mayj 'opine on whether a certain criteria is material to a Patent Office…not merely a "patent law expert," but also a former Solicitor of Patents and Trademarks at External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKinsey
Johnson and Johnson
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.